Orexo Ab (ORXOY) 18.3000 $ORXOY
Orexo signs exclusive reimbursement agreement for ZUBSOLV with UnitedHealth Group and OptumRx
M2 - Wed Mar 12, 8:24AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the signing of a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of ZUBSOLV.
Orexo closes on new SEK200m revolving credit facility
M2 - Thu Dec 12, 6:47AM CST
Orexo AB (STO: ORX.ST), a specialty pharmaceutical company, announced today the closing of a SEK200m revolving credit facility with Danske Bank.
Orexo's Abstral launched in Japan
M2 - Thu Dec 12, 6:42AM CST
Orexo AB (STO:ORX.ST), a specialty pharmaceutical company, announced today the commencement of the Japanese launch of Abstral by Kyowa Hakko Kirin Co Ltd.
Orexo reports change in number of shares and votes in November 2013
M2 - Mon Dec 02, 4:38AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday that there has been a change in its number of shares and votes as a result of the exercise of warrants in connection with the company's incentive programmes.
Global Opium (Opioid) Addiction Global Clinical Trials Review Report - H2 2013 Edition
M2 - Fri Nov 22, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/92tp9r/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" report to their offering. Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opium (Opioid) Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Universities Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials - Reckitt Benckiser Group Plc - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Butler Hospital - Johns Hopkins University - Lightlake Therapeutics Inc. - National Institute on Drug Abuse - New York State Psychiatric Institute - Omeros Corporation - Orexo AB - Pfizer Inc. - The Langton Centre - The University of Chicago - Titan Pharmaceuticals, Inc. - US WorldMeds, LLC - University of California, Los Angeles - University of California, San Francisco - University of Pennsylvania - Yale University For more information visit http://www.researchandmarkets.com/research/92...ium_opioid
Orexo's ADRs commence trading on OTCQX in the US
M2 - Thu Nov 14, 4:36AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Wednesday that its sponsored Level 1 American Depositary Receipts (ADRs) commenced trading on OTCQX International, a segment of the OTCQX marketplace in the US, on 13 November 2013, under the symbol 'ORXOY'.
Orexo AB Begins Trading on OTCQX®
PR Newswire - Wed Nov 13, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Orexo AB (OTCQX: ORXOY; OMX Nordic Exchange Stockholm: ORX), an emerging specialty pharmaceuticals company with commercial operations in the U.S. and research and development in Sweden, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX, the best marketplace with qualified companies.
Orexo receives approval for Abstral in Japan
M2 - Fri Sep 20, 5:00AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday receipt of the approval for Abstral (fentanyl) sublingual tablets in Japan.
/C O R R E C T I O N -- Orexo U.S./
PR Newswire - Mon Sep 16, 9:04AM CDT
In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued 16-Sep-2013 by Orexo U.S. over PR Newswire, we are advised by the company that the phone number in the fifth paragraph and the Orexo U.S., Inc. boilerplate, should read "1-855-ZUBSOLV" rather than "1-888-ZUBSOLV" as originally issued inadvertently. The complete, corrected release follows:
Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence
PR Newswire - Mon Sep 16, 7:00AM CDT
Orexo U.S. announced today that Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII) are commercially available in pharmacies across the United States. In July 2013, Zubsolv received approval from the U.S. Food and Drug Administration (FDA) for the maintenance treatment of opioid dependence. Zubsolv should be used as part of a complete treatment plan, including counseling and psychosocial support.
Acute Pain - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Acute Pain
M2 - Thu Sep 05, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3cmj8z/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Pain. - A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AcelRx Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - AngioChem Inc. - Array BioPharma Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - CombinatoRx, Incorporated - Cytogel Pharma, LLC - Encore Therapeutics Inc. - Esteve Group - Grunenthal GmbH - Intas Pharmaceuticals Ltd. - Iroko Pharmaceuticals, LLC - Madeira Therapeutics - Menarini Group - Nektar Therapeutics - NeuroTherapeutics Pharma Inc. - Nuvo Research Inc. - Orexo AB - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - QRxPharma Limited - RaQualia Pharma Inc. - Sigma-Tau S.p.A. - Trevena, Inc. For more information visit http://www.researchandmarkets.com/research/3cmj8z/acute_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Migraine - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gndq/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2013" report to their offering. 'Migraine - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Migraine pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Merck & Co., Inc. Biofrontera AG Dr. Reddy's Laboratories Limited Teva Pharmaceutical Industries Limited Zosano Pharma, Inc. Capnia, Inc. Revance Therapeutics, Inc. IntelGenx Technologies Corp. NovaDel Pharma, Inc. Paladin Labs Inc. POZEN Inc. Choongwae Pharma Corp Orexo AB D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/47gndq/migraine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Orexo signs exclusive reimbursement agreement for ZUBSOLV with UnitedHealth Group and OptumRx
M2 - Wed Mar 12, 8:24AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced today the signing of a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of ZUBSOLV.
Orexo closes on new SEK200m revolving credit facility
M2 - Thu Dec 12, 6:47AM CST
Orexo AB (STO: ORX.ST), a specialty pharmaceutical company, announced today the closing of a SEK200m revolving credit facility with Danske Bank.
Orexo's Abstral launched in Japan
M2 - Thu Dec 12, 6:42AM CST
Orexo AB (STO:ORX.ST), a specialty pharmaceutical company, announced today the commencement of the Japanese launch of Abstral by Kyowa Hakko Kirin Co Ltd.
Orexo reports change in number of shares and votes in November 2013
M2 - Mon Dec 02, 4:38AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday that there has been a change in its number of shares and votes as a result of the exercise of warrants in connection with the company's incentive programmes.
Global Opium (Opioid) Addiction Global Clinical Trials Review Report - H2 2013 Edition
M2 - Fri Nov 22, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/92tp9r/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" report to their offering. Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opium (Opioid) Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Universities Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials - Reckitt Benckiser Group Plc - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Butler Hospital - Johns Hopkins University - Lightlake Therapeutics Inc. - National Institute on Drug Abuse - New York State Psychiatric Institute - Omeros Corporation - Orexo AB - Pfizer Inc. - The Langton Centre - The University of Chicago - Titan Pharmaceuticals, Inc. - US WorldMeds, LLC - University of California, Los Angeles - University of California, San Francisco - University of Pennsylvania - Yale University For more information visit http://www.researchandmarkets.com/research/92...ium_opioid
Orexo's ADRs commence trading on OTCQX in the US
M2 - Thu Nov 14, 4:36AM CST
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Wednesday that its sponsored Level 1 American Depositary Receipts (ADRs) commenced trading on OTCQX International, a segment of the OTCQX marketplace in the US, on 13 November 2013, under the symbol 'ORXOY'.
Orexo AB Begins Trading on OTCQX®
PR Newswire - Wed Nov 13, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Orexo AB (OTCQX: ORXOY; OMX Nordic Exchange Stockholm: ORX), an emerging specialty pharmaceuticals company with commercial operations in the U.S. and research and development in Sweden, has chosen to have its American Depositary Receipts (ADRs) traded on OTCQX, the best marketplace with qualified companies.
Orexo receives approval for Abstral in Japan
M2 - Fri Sep 20, 5:00AM CDT
Specialty pharmaceutical company Orexo AB (STO:ORX.ST) announced on Friday receipt of the approval for Abstral (fentanyl) sublingual tablets in Japan.
/C O R R E C T I O N -- Orexo U.S./
PR Newswire - Mon Sep 16, 9:04AM CDT
In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued 16-Sep-2013 by Orexo U.S. over PR Newswire, we are advised by the company that the phone number in the fifth paragraph and the Orexo U.S., Inc. boilerplate, should read "1-855-ZUBSOLV" rather than "1-888-ZUBSOLV" as originally issued inadvertently. The complete, corrected release follows:
Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence
PR Newswire - Mon Sep 16, 7:00AM CDT
Orexo U.S. announced today that Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII) are commercially available in pharmacies across the United States. In July 2013, Zubsolv received approval from the U.S. Food and Drug Administration (FDA) for the maintenance treatment of opioid dependence. Zubsolv should be used as part of a complete treatment plan, including counseling and psychosocial support.
Acute Pain - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Acute Pain
M2 - Thu Sep 05, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3cmj8z/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Pain. - A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AcelRx Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - AngioChem Inc. - Array BioPharma Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - CombinatoRx, Incorporated - Cytogel Pharma, LLC - Encore Therapeutics Inc. - Esteve Group - Grunenthal GmbH - Intas Pharmaceuticals Ltd. - Iroko Pharmaceuticals, LLC - Madeira Therapeutics - Menarini Group - Nektar Therapeutics - NeuroTherapeutics Pharma Inc. - Nuvo Research Inc. - Orexo AB - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - QRxPharma Limited - RaQualia Pharma Inc. - Sigma-Tau S.p.A. - Trevena, Inc. For more information visit http://www.researchandmarkets.com/research/3cmj8z/acute_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Migraine - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gndq/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2013" report to their offering. 'Migraine - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Migraine pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Allergan, Inc. Amgen Inc. Questcor Pharmaceuticals, Inc. BioDelivery Sciences International, Inc. Merck & Co., Inc. Biofrontera AG Dr. Reddy's Laboratories Limited Teva Pharmaceutical Industries Limited Zosano Pharma, Inc. Capnia, Inc. Revance Therapeutics, Inc. IntelGenx Technologies Corp. NovaDel Pharma, Inc. Paladin Labs Inc. POZEN Inc. Choongwae Pharma Corp Orexo AB D-Pharm Ltd. Ache Laboratorios Farmaceuticos S/A Alder Biopharmaceuticals Inc. CoLucid Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/47gndq/migraine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
